GDF-11
A naturally occurring growth factor in the TGF-beta family that became famous in "young blood" rejuvenation research. The animal findings are genuinely contested, and there is no human evidence.
Quick take
- What it is: a naturally occurring growth factor in the TGF-beta / myostatin family.
- What people study it for: tissue rejuvenation and aging, after high-profile "young blood" experiments.
- What we actually know: animal results are genuinely contradictory; some studies suggest benefit, others suggest harm, and there are no human trials.
- Status: a research factor, not an approved drug.
What it is
GDF-11 (Growth Differentiation Factor 11) is a naturally occurring growth factor in the TGF-beta superfamily, closely related to myostatin (GDF-8). It became widely known through high-profile “young blood” experiments and is now a contested figure in aging research. It is a research factor, not an approved drug.1
It is included here because it is frequently discussed in longevity circles, often with more certainty than the science supports.
How it works
As a TGF-beta family signaling protein, GDF-11 acts on receptors that regulate cell growth, differentiation and development, overlapping with the pathways used by myostatin.1,2 The original interest came from parabiosis experiments (joining the circulations of young and old animals), which suggested that a youthful blood factor — proposed to be GDF-11 — might restore aspects of aging tissue. Because GDF-11 and myostatin share machinery, isolating GDF-11’s specific effects is scientifically difficult.
What the evidence shows
Animal studies
This is the crux of the GDF-11 story: the animal evidence is genuinely conflicting. Some studies reported rejuvenating effects on muscle, heart and brain in older mice.2 Other studies challenged these results — citing problems with how GDF-11 was measured and distinguished from myostatin, and reporting that GDF-11 could impair muscle regeneration rather than improve it.3 The net picture is unsettled.
Human studies
There are no human clinical trials establishing GDF-11 as a treatment for aging or anything else.3 Human relevance, dosing and safety are not established, and the contradictory animal data make extrapolation especially unreliable.
Dosages reported in the literature
Informational only. The figures below refer to research settings; they are not a recommendation or a prescription. GDF-11 is not approved, has no human trials, and no safe or effective human dose exists.
| Setting | Route | Reported range |
|---|---|---|
| Animal studies | Injection (research) | Defined by study protocol; not applicable to humans |
| Human use | — | No human dose established; not studied in people |
Because there is no human research, nothing here should be read as a usable dose.
Safety & side effects
There are no human safety data for administered GDF-11.3 Beyond that gap, the conflicting animal data raise specific concerns — including the possibility that GDF-11, like its relative myostatin, could suppress muscle rather than rejuvenate it. As with all unregulated research proteins, identity and purity of material sold online cannot be assumed.
Legal & regulatory status
GDF-11 is not approved by the FDA for any use; it is a research factor. Marketing it as a therapeutic or anti-aging product would fall outside any established regulatory status. Rules differ by country and change over time.1
References
- Walker RG, Poggioli T, Katsimpardi L, Buchanan SM, Oh J, Wattrus S, Heidecker B, Fong YW, Rubin LL, Ganz P, Thompson TB, Wagers AJ, Lee SJ. Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation. Circulation Research. 2016 Apr 1;118(7):1125-1141. [PMID 27034275, doi:10.1161/CIRCRESAHA.116.308391]
- Primary heart-rejuvenation paper: Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, Sinha M, Dall’Osso C, Khong D, Shadrach JL, Miller CM, Singer BS, Stewart A, Psychogios N, Gerszten RE, Lee RT, Wagers AJ, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013 May 9;153(4):828-839. | Skeletal muscle: Sinha M, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014 May 9;344(6184):649-652. | Brain: Katsimpardi L, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014 May 9;344(6184):630-634. [PMID 23663781, PMID 24797481, PMID 24797482, doi:10.1016/j.cell.2013.04.015]
- Egerman MA, Cadena SM, Gilbert JA, Meyer A, Nelson HN, Swalley SE, Mallozzi C, Jacobi C, Jennings LL, Clay I, Laurent G, Ma S, Brachat S, Lach-Trifilieff E, Shavlakadze T, Trendelenburg AU, Brack AS, Glass DJ. GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration. Cell Metabolism. 2015 Jul 7;22(1):164-174. | Accompanying commentary: Brun CE, Rudnicki MA. GDF11 and the Mythical Fountain of Youth. Cell Metabolism. 2015 Jul 7;22(1):54-56. [PMID 26001423, PMID 26003784, doi:10.1016/j.cmet.2015.05.010, doi:10.1016/j.cmet.2015.05.009]